CY1124366T1 - Μεθοδοι αυξησης τονικης αναστολης και θεραπειας της δευτερογενους αϋπνιας - Google Patents
Μεθοδοι αυξησης τονικης αναστολης και θεραπειας της δευτερογενους αϋπνιαςInfo
- Publication number
- CY1124366T1 CY1124366T1 CY20211100509T CY211100509T CY1124366T1 CY 1124366 T1 CY1124366 T1 CY 1124366T1 CY 20211100509 T CY20211100509 T CY 20211100509T CY 211100509 T CY211100509 T CY 211100509T CY 1124366 T1 CY1124366 T1 CY 1124366T1
- Authority
- CY
- Cyprus
- Prior art keywords
- sleep
- subject
- increasing
- methods
- reduction
- Prior art date
Links
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title abstract 3
- 230000009478 tonic inhibition Effects 0.000 title abstract 3
- 230000007958 sleep Effects 0.000 abstract 7
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 230000037046 slow wave activity Effects 0.000 abstract 2
- 230000037322 slow-wave sleep Effects 0.000 abstract 2
- ZDZDSZQYRBZPNN-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-6-ium-3-olate;hydrochloride Chemical compound Cl.C1NCCC2=C1ONC2=O ZDZDSZQYRBZPNN-UHFFFAOYSA-N 0.000 abstract 1
- 208000009575 Angelman syndrome Diseases 0.000 abstract 1
- 208000001914 Fragile X syndrome Diseases 0.000 abstract 1
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000004622 sleep time Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462008939P | 2014-06-06 | 2014-06-06 | |
| PCT/US2015/034018 WO2015187851A1 (en) | 2014-06-06 | 2015-06-03 | Methods of increasing tonic inhibition and treating secondary insomnia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124366T1 true CY1124366T1 (el) | 2022-07-22 |
Family
ID=54767324
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100509T CY1124366T1 (el) | 2014-06-06 | 2021-06-10 | Μεθοδοι αυξησης τονικης αναστολης και θεραπειας της δευτερογενους αϋπνιας |
| CY20211100510T CY1124368T1 (el) | 2014-06-06 | 2021-06-10 | Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100510T CY1124368T1 (el) | 2014-06-06 | 2021-06-10 | Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman |
Country Status (20)
| Country | Link |
|---|---|
| US (11) | US20150352085A1 (enExample) |
| EP (3) | EP3372229B1 (enExample) |
| JP (4) | JP2017516868A (enExample) |
| AR (1) | AR100772A1 (enExample) |
| AU (4) | AU2015269667B2 (enExample) |
| CA (1) | CA2950845C (enExample) |
| CY (2) | CY1124366T1 (enExample) |
| DK (2) | DK3151832T3 (enExample) |
| ES (2) | ES2876350T3 (enExample) |
| HR (2) | HRP20210901T1 (enExample) |
| HU (2) | HUE055400T2 (enExample) |
| IL (2) | IL249287B (enExample) |
| LT (2) | LT3151832T (enExample) |
| MX (2) | MX380868B (enExample) |
| PL (2) | PL3372229T3 (enExample) |
| PT (2) | PT3372229T (enExample) |
| RS (2) | RS62006B1 (enExample) |
| SI (2) | SI3372229T1 (enExample) |
| SM (2) | SMT202100340T1 (enExample) |
| WO (1) | WO2015187851A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3372229T3 (pl) | 2014-06-06 | 2021-10-04 | Ovid Therapeutics, Inc. | Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana |
| US10080898B2 (en) * | 2015-05-29 | 2018-09-25 | Medtronic, Inc. | Simultaneous physiological sensing and stimulation with saturation detection |
| US10434308B2 (en) | 2015-05-29 | 2019-10-08 | Medtronic, Inc. | Impedance matching and electrode conditioning in patient interface systems |
| US9682069B2 (en) | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
| MX391708B (es) | 2015-07-17 | 2025-03-21 | Ovid Therapeutics Inc | Metodos para tratar trastornos del desarrollo con gaboxadol. |
| WO2018017639A1 (en) * | 2016-07-19 | 2018-01-25 | Georgia State University Research Foundation | Methods for treating rett syndrome |
| MX2019001669A (es) | 2016-08-11 | 2019-09-27 | Ovid Therapeutics Inc | Metodos y composiciones para el tratamiento de trastornos epilepticos. |
| AU2017363598A1 (en) * | 2016-11-22 | 2019-05-23 | Ovid Therapeutics Inc. | Methods of treating developmental disorders and/or seizure disorders with flupirtine |
| US10071083B2 (en) * | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| US20180338959A1 (en) * | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
| KR20200047557A (ko) | 2017-08-04 | 2020-05-07 | 오비드 테라퓨틱스 인크. | 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용 |
| US11181384B2 (en) * | 2018-07-23 | 2021-11-23 | Waymo Llc | Verifying map data using challenge questions |
| KR20210062662A (ko) | 2018-09-20 | 2021-05-31 | 오비드 테라퓨틱스 인크. | 투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용 |
| CN113395962A (zh) * | 2018-11-21 | 2021-09-14 | Certego治疗公司 | 加波沙朵用于降低自杀风险和快速缓解抑郁症 |
| WO2020131856A1 (en) | 2018-12-17 | 2020-06-25 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| US20210015760A1 (en) * | 2019-07-15 | 2021-01-21 | Ovid Therapeutics Inc. | Pharmaceutical formulations containing gaboxadol for therapeutic treatment |
| AU2020405060A1 (en) | 2019-12-18 | 2022-06-09 | Ovid Therapeutics Inc. | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome |
| AU2021275863A1 (en) | 2020-05-20 | 2023-02-02 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
| JP7600661B2 (ja) * | 2020-12-11 | 2024-12-17 | ａｒｔｉｅｎｃｅ株式会社 | 貼付剤 |
| US20240285562A1 (en) * | 2023-02-17 | 2024-08-29 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270278A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Cycliske aminosyrer |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
| DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| DE19526864A1 (de) | 1995-07-22 | 1997-01-23 | Labtec Gmbh | Hormonpflaster |
| US6461644B1 (en) | 1996-03-25 | 2002-10-08 | Richard R. Jackson | Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| US6676961B1 (en) | 2002-03-06 | 2004-01-13 | Automated Carrier Technologies, Inc. | Transdermal patch assembly |
| US20050137222A1 (en) * | 2003-12-18 | 2005-06-23 | H. Lundbeck A/S | Treatment of insomnia in human patients |
| MXPA06011325A (es) | 2004-04-02 | 2006-12-15 | Lundbeck & Co As H | Tratamiento de la funcion respiratoria alterada con gaboxadol. |
| DE102005020882A1 (de) * | 2005-05-04 | 2006-11-09 | Dömling, Alexander, Dr. | Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten |
| US20110046090A1 (en) * | 2005-10-31 | 2011-02-24 | Braincells Inc. | Modulation of neurogenesis with gaba agents and gaba analogs |
| US20090143335A1 (en) | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
| WO2009064928A1 (en) | 2007-11-13 | 2009-05-22 | Cadence Pharmaceuticals | Reduced dose intravenous acetaminophen |
| CA2732636A1 (en) * | 2008-09-01 | 2009-05-07 | H. Lundbeck A/S | Pharmaceutical composition comprising gaboxadol and an inhibitor of pat1 or oat |
| PL3372229T3 (pl) | 2014-06-06 | 2021-10-04 | Ovid Therapeutics, Inc. | Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana |
| MX391708B (es) * | 2015-07-17 | 2025-03-21 | Ovid Therapeutics Inc | Metodos para tratar trastornos del desarrollo con gaboxadol. |
| US9399034B1 (en) | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
-
2015
- 2015-06-03 PL PL18169211T patent/PL3372229T3/pl unknown
- 2015-06-03 EP EP18169211.2A patent/EP3372229B1/en active Active
- 2015-06-03 PT PT181692112T patent/PT3372229T/pt unknown
- 2015-06-03 DK DK15803364.7T patent/DK3151832T3/da active
- 2015-06-03 EP EP15803364.7A patent/EP3151832B1/en active Active
- 2015-06-03 HU HUE18169211A patent/HUE055400T2/hu unknown
- 2015-06-03 PT PT158033647T patent/PT3151832T/pt unknown
- 2015-06-03 DK DK18169211.2T patent/DK3372229T3/da active
- 2015-06-03 SM SM20210340T patent/SMT202100340T1/it unknown
- 2015-06-03 LT LTEP15803364.7T patent/LT3151832T/lt unknown
- 2015-06-03 HU HUE15803364A patent/HUE055155T2/hu unknown
- 2015-06-03 SI SI201531620T patent/SI3372229T1/sl unknown
- 2015-06-03 RS RS20210711A patent/RS62006B1/sr unknown
- 2015-06-03 EP EP20204995.3A patent/EP3795156A1/en active Pending
- 2015-06-03 AU AU2015269667A patent/AU2015269667B2/en active Active
- 2015-06-03 HR HRP20210901TT patent/HRP20210901T1/hr unknown
- 2015-06-03 MX MX2016016136A patent/MX380868B/es unknown
- 2015-06-03 SI SI201531616T patent/SI3151832T1/sl unknown
- 2015-06-03 ES ES15803364T patent/ES2876350T3/es active Active
- 2015-06-03 CA CA2950845A patent/CA2950845C/en active Active
- 2015-06-03 MX MX2020012404A patent/MX391502B/es unknown
- 2015-06-03 RS RS20210718A patent/RS62007B1/sr unknown
- 2015-06-03 JP JP2017516256A patent/JP2017516868A/ja not_active Withdrawn
- 2015-06-03 PL PL15803364T patent/PL3151832T3/pl unknown
- 2015-06-03 SM SM20210343T patent/SMT202100343T1/it unknown
- 2015-06-03 LT LTEP18169211.2T patent/LT3372229T/lt unknown
- 2015-06-03 ES ES18169211T patent/ES2875742T3/es active Active
- 2015-06-03 WO PCT/US2015/034018 patent/WO2015187851A1/en not_active Ceased
- 2015-06-03 US US14/729,910 patent/US20150352085A1/en not_active Abandoned
- 2015-06-05 AR ARP150101808A patent/AR100772A1/es not_active Application Discontinuation
- 2015-10-19 US US14/886,764 patent/US9339495B2/en active Active
-
2016
- 2016-04-19 US US15/132,641 patent/US9446028B2/en active Active
- 2016-11-04 US US15/343,690 patent/US9744159B2/en active Active
- 2016-11-29 IL IL249287A patent/IL249287B/en active IP Right Grant
- 2016-12-12 US US15/375,735 patent/US9801864B2/en active Active
-
2017
- 2017-06-09 US US15/618,736 patent/US20170273956A1/en not_active Abandoned
- 2017-09-27 US US15/716,726 patent/US20180015076A1/en not_active Abandoned
-
2018
- 2018-06-29 US US16/023,282 patent/US11278529B2/en active Active
-
2019
- 2019-08-27 IL IL268960A patent/IL268960B/en active IP Right Grant
- 2019-11-29 JP JP2019217208A patent/JP2020063264A/ja not_active Withdrawn
-
2020
- 2020-08-11 AU AU2020217342A patent/AU2020217342B2/en active Active
-
2021
- 2021-06-07 HR HRP20210902TT patent/HRP20210902T1/hr unknown
- 2021-06-10 CY CY20211100509T patent/CY1124366T1/el unknown
- 2021-06-10 CY CY20211100510T patent/CY1124368T1/el unknown
- 2021-07-15 JP JP2021116935A patent/JP2021178836A/ja not_active Withdrawn
- 2021-09-30 US US17/490,650 patent/US20220016091A1/en not_active Abandoned
-
2022
- 2022-01-07 AU AU2022200085A patent/AU2022200085A1/en not_active Abandoned
- 2022-08-08 US US17/882,939 patent/US20230051859A1/en not_active Abandoned
-
2023
- 2023-05-30 JP JP2023088456A patent/JP2023123442A/ja active Pending
-
2024
- 2024-04-22 AU AU2024202604A patent/AU2024202604A1/en active Pending
- 2024-10-03 US US18/905,678 patent/US20250025448A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124366T1 (el) | Μεθοδοι αυξησης τονικης αναστολης και θεραπειας της δευτερογενους αϋπνιας | |
| CY1122624T1 (el) | Θεραπεια συνδυασμου του καρκινου | |
| CY1125089T1 (el) | Μεθοδοι για τη θεραπεια μολυνσεων απο coronaviridae | |
| CY1124298T1 (el) | Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet | |
| CY1123688T1 (el) | Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20 | |
| CY1121228T1 (el) | 19-νορ c3,3-διϋποκατεστημενα c21-n-πypazoλyλ στεροειδη και μεθοδοι χρησης αυτων | |
| MX2024010140A (es) | Nuevos metodos. | |
| MX388781B (es) | Compuestos de quinazolina sustituido y su uso como inhibidores de proteínas kras, hras y/o nras mutantes g12c. | |
| CL2018000119A1 (es) | Compuestos pirazolo[1,5-a]piridina sustituidos como inhibidores de quinasa de ret. | |
| CY1124078T1 (el) | Συνθεσεις που περιλαμβανουν αναστολεα λυσινης ειδικης απομεθυλασης-1 που εχει δακτυλιο πυριμιδινης και χρηση αυτων στη θεραπεια καρκινου | |
| EA201690212A1 (ru) | Способы лечения или профилактики офтальмологических патологических состояний | |
| CY1119939T1 (el) | Παραγωγα 2,3-διϋδρο-βενζο[1,4]οξαζιν και σχετικες ενωσεις οπως αναστολεις φωσφοϊνοσιτινης-3 κινασης (ρι3κ) για τη θεραπεια παραδειγματος χαρην της ρευματοειδους αρθριτιδας | |
| CY1121997T1 (el) | Κρυσταλλικες μορφες του 2-((4s)-6-(4-χλωροφαινυλ)-1-μεθυλ-4η-βενζο[c]ισοξαζολo[4,5-ε]αζεπιν-4-υλ)ακεταμιδιου | |
| UY36308A (es) | Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso | |
| CY1119642T1 (el) | Csf-1r αναστολεις για την θεραπεια ογκων του εγκεφαλου | |
| EA201792116A1 (ru) | Ингибитор янус-киназы | |
| MX382754B (es) | Terapias combinadas para tratar el cancer. | |
| CY1123216T1 (el) | Αναστολεις της gls1 για την αντιμετωπιση νοσων | |
| CY1120026T1 (el) | Κρενολανιμπη για την θεραπεια μεταλλαγμενων me flt3 πολλαπλασιαστικων διαταραχων | |
| MX389927B (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| EA201692436A1 (ru) | Медицинское применение | |
| TN2018000195A1 (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| CY1123501T1 (el) | Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος | |
| CY1121628T1 (el) | 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης | |
| RU2017131448A (ru) | Способ лечения опухоли головного мозга |